Global Oncolytic Virus Therapy Market review

Oncolytic Virus Therapy Comprehensive Study by Type (Onxy-15, RIGVIR, Talimogene laherparepvec (T-VEC), Reolysin), Application (Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Others) Players and Region - Global Market Outlook to 2032

Oncolytic Virus Therapy Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Type
  • Onxy-15
  • RIGVIR
  • Talimogene laherparepvec (T-VEC)
  • Reolysin
By Application
  • Lung Cancer
  • Prostate Cancer
  • Melanoma
  • Brain Tumor
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing number of cancer patients
      • 3.2.2. Increasing awareness regarding very less toxic effect as compared to other conventional and chemotherapy
    • 3.3. Market Trends
      • 3.3.1. 48 oncolytic virus therapy are available in the market
      • 3.3.2. Imlygic is an advanced therapy widely used
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncolytic Virus Therapy, by Type, Application and Region (value and price ) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Oncolytic Virus Therapy (Value)
      • 5.2.1. Global Oncolytic Virus Therapy by: Type (Value)
        • 5.2.1.1. Onxy-15
        • 5.2.1.2. RIGVIR
        • 5.2.1.3. Talimogene laherparepvec (T-VEC)
        • 5.2.1.4. Reolysin
      • 5.2.2. Global Oncolytic Virus Therapy by: Application (Value)
        • 5.2.2.1. Lung Cancer
        • 5.2.2.2. Prostate Cancer
        • 5.2.2.3. Melanoma
        • 5.2.2.4. Brain Tumor
        • 5.2.2.5. Others
      • 5.2.3. Global Oncolytic Virus Therapy Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Oncolytic Virus Therapy (Price)
      • 5.3.1. Global Oncolytic Virus Therapy by: Type (Price)
  • 6. Oncolytic Virus Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Crusade Laboratories (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genelux Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Oncolytics Biotech (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Oncos Therapeutics (Finland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Jennerex Biotherapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lokon Pharma (Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MultiVir (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Oncolys BioPharma (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioVex (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cell Genesys (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. PsiOxus Therapeutics (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Shanghai Sunway Bioteh (China)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Oncolytic Virus Therapy Sale, by Type, Application and Region (value and price ) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Oncolytic Virus Therapy (Value)
      • 7.2.1. Global Oncolytic Virus Therapy by: Type (Value)
        • 7.2.1.1. Onxy-15
        • 7.2.1.2. RIGVIR
        • 7.2.1.3. Talimogene laherparepvec (T-VEC)
        • 7.2.1.4. Reolysin
      • 7.2.2. Global Oncolytic Virus Therapy by: Application (Value)
        • 7.2.2.1. Lung Cancer
        • 7.2.2.2. Prostate Cancer
        • 7.2.2.3. Melanoma
        • 7.2.2.4. Brain Tumor
        • 7.2.2.5. Others
      • 7.2.3. Global Oncolytic Virus Therapy Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Oncolytic Virus Therapy (Price)
      • 7.3.1. Global Oncolytic Virus Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncolytic Virus Therapy: by Type(USD Million)
  • Table 2. Oncolytic Virus Therapy Onxy-15 , by Region USD Million (2019-2024)
  • Table 3. Oncolytic Virus Therapy RIGVIR , by Region USD Million (2019-2024)
  • Table 4. Oncolytic Virus Therapy Talimogene laherparepvec (T-VEC) , by Region USD Million (2019-2024)
  • Table 5. Oncolytic Virus Therapy Reolysin , by Region USD Million (2019-2024)
  • Table 6. Oncolytic Virus Therapy: by Application(USD Million)
  • Table 7. Oncolytic Virus Therapy Lung Cancer , by Region USD Million (2019-2024)
  • Table 8. Oncolytic Virus Therapy Prostate Cancer , by Region USD Million (2019-2024)
  • Table 9. Oncolytic Virus Therapy Melanoma , by Region USD Million (2019-2024)
  • Table 10. Oncolytic Virus Therapy Brain Tumor , by Region USD Million (2019-2024)
  • Table 11. Oncolytic Virus Therapy Others , by Region USD Million (2019-2024)
  • Table 12. South America Oncolytic Virus Therapy, by Country USD Million (2019-2024)
  • Table 13. South America Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 14. South America Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 15. Brazil Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 16. Brazil Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 17. Argentina Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 18. Argentina Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 19. Rest of South America Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 20. Rest of South America Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 21. Asia Pacific Oncolytic Virus Therapy, by Country USD Million (2019-2024)
  • Table 22. Asia Pacific Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 23. Asia Pacific Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 24. China Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 25. China Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 26. Japan Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 27. Japan Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 28. India Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 29. India Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 30. South Korea Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 31. South Korea Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 32. Taiwan Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 33. Taiwan Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 34. Australia Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 35. Australia Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 36. Rest of Asia-Pacific Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 37. Rest of Asia-Pacific Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 38. Europe Oncolytic Virus Therapy, by Country USD Million (2019-2024)
  • Table 39. Europe Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 40. Europe Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 41. Germany Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 42. Germany Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 43. France Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 44. France Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 45. Italy Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 46. Italy Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 47. United Kingdom Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 48. United Kingdom Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 49. Netherlands Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 50. Netherlands Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 51. Rest of Europe Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 52. Rest of Europe Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 53. MEA Oncolytic Virus Therapy, by Country USD Million (2019-2024)
  • Table 54. MEA Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 55. MEA Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 56. Middle East Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 57. Middle East Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 58. Africa Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 59. Africa Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 60. North America Oncolytic Virus Therapy, by Country USD Million (2019-2024)
  • Table 61. North America Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 62. North America Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 63. United States Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 64. United States Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 65. Canada Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 66. Canada Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 67. Mexico Oncolytic Virus Therapy, by Type USD Million (2019-2024)
  • Table 68. Mexico Oncolytic Virus Therapy, by Application USD Million (2019-2024)
  • Table 69. Oncolytic Virus Therapy: by Type(USD/Units)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Oncolytic Virus Therapy: by Type(USD Million)
  • Table 84. Oncolytic Virus Therapy Onxy-15 , by Region USD Million (2027-2032)
  • Table 85. Oncolytic Virus Therapy RIGVIR , by Region USD Million (2027-2032)
  • Table 86. Oncolytic Virus Therapy Talimogene laherparepvec (T-VEC) , by Region USD Million (2027-2032)
  • Table 87. Oncolytic Virus Therapy Reolysin , by Region USD Million (2027-2032)
  • Table 88. Oncolytic Virus Therapy: by Application(USD Million)
  • Table 89. Oncolytic Virus Therapy Lung Cancer , by Region USD Million (2027-2032)
  • Table 90. Oncolytic Virus Therapy Prostate Cancer , by Region USD Million (2027-2032)
  • Table 91. Oncolytic Virus Therapy Melanoma , by Region USD Million (2027-2032)
  • Table 92. Oncolytic Virus Therapy Brain Tumor , by Region USD Million (2027-2032)
  • Table 93. Oncolytic Virus Therapy Others , by Region USD Million (2027-2032)
  • Table 94. South America Oncolytic Virus Therapy, by Country USD Million (2027-2032)
  • Table 95. South America Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 96. South America Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 97. Brazil Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 98. Brazil Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 99. Argentina Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 100. Argentina Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 101. Rest of South America Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 102. Rest of South America Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 103. Asia Pacific Oncolytic Virus Therapy, by Country USD Million (2027-2032)
  • Table 104. Asia Pacific Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 105. Asia Pacific Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 106. China Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 107. China Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 108. Japan Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 109. Japan Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 110. India Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 111. India Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 112. South Korea Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 113. South Korea Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 114. Taiwan Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 115. Taiwan Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 116. Australia Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 117. Australia Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 118. Rest of Asia-Pacific Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 119. Rest of Asia-Pacific Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 120. Europe Oncolytic Virus Therapy, by Country USD Million (2027-2032)
  • Table 121. Europe Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 122. Europe Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 123. Germany Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 124. Germany Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 125. France Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 126. France Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 127. Italy Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 128. Italy Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 129. United Kingdom Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 130. United Kingdom Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 131. Netherlands Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 132. Netherlands Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 133. Rest of Europe Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 134. Rest of Europe Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 135. MEA Oncolytic Virus Therapy, by Country USD Million (2027-2032)
  • Table 136. MEA Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 137. MEA Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 138. Middle East Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 139. Middle East Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 140. Africa Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 141. Africa Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 142. North America Oncolytic Virus Therapy, by Country USD Million (2027-2032)
  • Table 143. North America Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 144. North America Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 145. United States Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 146. United States Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 147. Canada Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 148. Canada Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 149. Mexico Oncolytic Virus Therapy, by Type USD Million (2027-2032)
  • Table 150. Mexico Oncolytic Virus Therapy, by Application USD Million (2027-2032)
  • Table 151. Oncolytic Virus Therapy: by Type(USD/Units)
  • Table 152. Research Programs/Design for This Report
  • Table 153. Key Data Information from Secondary Sources
  • Table 154. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncolytic Virus Therapy: by Type USD Million (2019-2024)
  • Figure 5. Global Oncolytic Virus Therapy: by Application USD Million (2019-2024)
  • Figure 6. South America Oncolytic Virus Therapy Share (%), by Country
  • Figure 7. Asia Pacific Oncolytic Virus Therapy Share (%), by Country
  • Figure 8. Europe Oncolytic Virus Therapy Share (%), by Country
  • Figure 9. MEA Oncolytic Virus Therapy Share (%), by Country
  • Figure 10. North America Oncolytic Virus Therapy Share (%), by Country
  • Figure 11. Global Oncolytic Virus Therapy: by Type USD/Units (2019-2024)
  • Figure 12. Global Oncolytic Virus Therapy share by Players 2024 (%)
  • Figure 13. Global Oncolytic Virus Therapy share by Players (Top 3) 2024(%)
  • Figure 14. Global Oncolytic Virus Therapy share by Players (Top 5) 2024(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Crusade Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Crusade Laboratories (United Kingdom) Revenue: by Geography 2024
  • Figure 18. Genelux Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Genelux Corporation (United States) Revenue: by Geography 2024
  • Figure 20. Oncolytics Biotech (Canada) Revenue, Net Income and Gross profit
  • Figure 21. Oncolytics Biotech (Canada) Revenue: by Geography 2024
  • Figure 22. Oncos Therapeutics (Finland) Revenue, Net Income and Gross profit
  • Figure 23. Oncos Therapeutics (Finland) Revenue: by Geography 2024
  • Figure 24. Jennerex Biotherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Jennerex Biotherapeutics (United States) Revenue: by Geography 2024
  • Figure 26. Lokon Pharma (Sweden) Revenue, Net Income and Gross profit
  • Figure 27. Lokon Pharma (Sweden) Revenue: by Geography 2024
  • Figure 28. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck (United States) Revenue: by Geography 2024
  • Figure 30. MultiVir (United States) Revenue, Net Income and Gross profit
  • Figure 31. MultiVir (United States) Revenue: by Geography 2024
  • Figure 32. Oncolys BioPharma (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Oncolys BioPharma (Japan) Revenue: by Geography 2024
  • Figure 34. BioVex (United States) Revenue, Net Income and Gross profit
  • Figure 35. BioVex (United States) Revenue: by Geography 2024
  • Figure 36. Cell Genesys (United States) Revenue, Net Income and Gross profit
  • Figure 37. Cell Genesys (United States) Revenue: by Geography 2024
  • Figure 38. PsiOxus Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. PsiOxus Therapeutics (United Kingdom) Revenue: by Geography 2024
  • Figure 40. Shanghai Sunway Bioteh (China) Revenue, Net Income and Gross profit
  • Figure 41. Shanghai Sunway Bioteh (China) Revenue: by Geography 2024
  • Figure 42. Global Oncolytic Virus Therapy: by Type USD Million (2027-2032)
  • Figure 43. Global Oncolytic Virus Therapy: by Application USD Million (2027-2032)
  • Figure 44. South America Oncolytic Virus Therapy Share (%), by Country
  • Figure 45. Asia Pacific Oncolytic Virus Therapy Share (%), by Country
  • Figure 46. Europe Oncolytic Virus Therapy Share (%), by Country
  • Figure 47. MEA Oncolytic Virus Therapy Share (%), by Country
  • Figure 48. North America Oncolytic Virus Therapy Share (%), by Country
  • Figure 49. Global Oncolytic Virus Therapy: by Type USD/Units (2027-2032)
List of companies from research coverage that are profiled in the study
  • Crusade Laboratories (United Kingdom)
  • Genelux Corporation (United States)
  • Oncolytics Biotech (Canada)
  • Oncos Therapeutics (Finland)
  • Jennerex Biotherapeutics (United States)
  • Lokon Pharma (Sweden)
  • Merck (United States)
  • MultiVir (United States)
  • Oncolys BioPharma (Japan)
  • BioVex (United States)
  • Cell Genesys (United States)
  • PsiOxus Therapeutics (United Kingdom)
  • Shanghai Sunway Bioteh (China)
Additional players considered in the study are as follows:
Takara Bio (Japan) , VCN Biosciences (Spain) , ViroTarg (Australia) , Vyriad (United States)
Select User Access Type

Key Highlights of Report


Nov 2021 156 Pages 73 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oncolytic Virus Therapy Market review Quantitative research analysis
Global Oncolytic Virus Therapy Market review Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Oncolytic Virus Therapy Market review Report?

Have a Query? Click Here

Other Related Reports

Dental Practice Management Software Comprehensive Study by Application (Patient Management & Billing, Insurance And Claim Tools, Clinical Applications), Deployment Mode (On-premise, Web-based, Cloud-...
$ 3750
Healthcare BPO Comprehensive Study by Type (Patient Enrollment and Strategic Planning, Medical Billing, Medical Transcription, Device Monitoring, Revenue Cycle Management), Payer Service (Human Resou...
$ 3750
Healthcare Artificial Intelligence Comprehensive Study by Application (Patient data and Risk analysis, Inpatient care & Hospital Management, Medical Imaging and Diagnostics, Lifestyle Management and ...
$ 3750
E-Clinical Solution Software Comprehensive Study by Type (Clinical Data Management Solution, Clinical Trial Management Software, Electronic Clinical Outcome Assessment, Electronic Trial Master File, ...
$ 3750
SPECT Systems Comprehensive Study by Type (Hybrid SPECT, Standalone SPECT), Application (Cardiology, Oncology, General imaging, Neurology), End User (Hospitals, Imaging Centers, Academic and Research...
$ 3500
Telemedicine Comprehensive Study by Type (Telehospitals, Telehomes, MHealth (mobile health)), Application (Teleconsultation, Telecardiology, Teleradiology, Telepathology, Teledermatology, Tele Home h...
$ 3750